Related Experiment Video
Updated: Aug 17, 2026

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
Published on: October 3, 2011
Life-Limiting Peripheral Organ Dysfunction in Feline Sandhoff Disease Emerges after Effective CNS Gene Therapy
Aime K Johnson1, Victoria J McCurdy2,3, Heather L Gray-Edwards2
1Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA.
Insights
Adeno-associated virus (AAV) gene therapy successfully treated feline Sandhoff disease, significantly extending lifespan and clearing neurological ganglioside storage. Whole-body targeting is crucial for future treatments.
Area of Science:
- Neuroscience
- Genetics
- Biotechnology
Background:
- GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases, is a fatal neurodegenerative disorder with no current effective treatments.
- Children with GM2 gangliosidosis typically succumb by age five after a prolonged period of neurodegeneration.
Purpose of the Study:
- To advance adeno-associated virus (AAV) gene therapy for potential human translation in treating GM2 gangliosidosis.
- To evaluate the efficacy of AAV-mediated gene therapy in a feline model of Sandhoff disease.
Main Methods:
- Feline models of Sandhoff disease received intracranial injections of vectors encoding feline β-N-acetylhexosaminidase.
- Hexosaminidase activity and ganglioside storage were assessed in the central nervous system and throughout the body post-treatment.
Main Results:
- AAV gene therapy normalized hexosaminidase activity and significantly reduced ganglioside storage in the brain and spinal cord.
- Treated cats showed a marked increase in lifespan, from 4.4 months to 19.1 months, with some surviving over 21 months.
- While central nervous system pathology was corrected, peripheral tissues, particularly the enteric nervous system, remained inadequately treated, leading to secondary complications.
Conclusions:
- AAV gene therapy effectively addresses neuropathology in feline Sandhoff disease, offering a promising therapeutic strategy.
- The study highlights the need for whole-body targeting in future gene therapy approaches to fully address systemic manifestations of GM2 gangliosidosis.
Objective:
GM2 gangliosidosis is usually fatal by 5 years of age in its 2 major subtypes, Tay-Sachs and Sandhoff disease. First reported in 1881, GM2 gangliosidosis has no effective treatment today, and children succumb to the disease after a protracted neurodegenerative course and semi-vegetative state. This study seeks to further develop adeno-associated virus (AAV) gene therapy for human translation.
Methods:
Cats with Sandhoff disease were treated by intracranial injection of vectors expressing feline β-N-acetylhexosaminidase, the enzyme deficient in GM2 gangliosidosis.
Results:
Hexosaminidase activity throughout the brain and spinal cord was above normal after treatment, with highest activities at the injection sites (thalamus and deep cerebellar nuclei). Ganglioside storage was reduced throughout the brain and spinal cord, with near complete clearance in many regions. While untreated cats with Sandhoff disease lived for 4.4 ± 0.6 months, AAV-treated cats lived to 19.1 ± 8.6 months, and 3 of 9 cats lived >21 months. Correction of the central nervous system was so effective that significant increases in lifespan led to the emergence of otherwise subclinical peripheral disease, including megacolon, enlarged stomach and urinary bladder, soft tissue spinal cord compression, and patellar luxation. Throughout the gastrointestinal tract, neurons of the myenteric and submucosal plexuses developed profound pathology, demonstrating that the enteric nervous system was inadequately treated.
Interpretation:
The vector formulation in the current study effectively treats neuropathology in feline Sandhoff disease, but whole-body targeting will be an important consideration in next-generation approaches. ANN NEUROL 2023;94:969-986.
Related Concept Videos
Pleiotropy
In-vitro Mutagenesis
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

